Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C33H36N2O12.2ClH |
| Molecular Weight | 725.567 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CCOC(=O)C1=CC(=O)C2=C(OCC(COC3=C4C(=O)C=C(OC4=CC=C3)C(=O)OCC)OC(=O)[C@@H](N)CCCCN)C=CC=C2O1
InChI
InChIKey=VZZTWOVKCVPTSM-FJSYBICCSA-N
InChI=1S/C33H36N2O12.2ClH/c1-3-41-32(39)27-15-21(36)29-23(10-7-12-25(29)46-27)43-17-19(45-31(38)20(35)9-5-6-14-34)18-44-24-11-8-13-26-30(24)22(37)16-28(47-26)33(40)42-4-2;;/h7-8,10-13,15-16,19-20H,3-6,9,14,17-18,34-35H2,1-2H3;2*1H/t20-;;/m0../s1
| Molecular Formula | C33H36N2O12 |
| Molecular Weight | 652.6451 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/75-271_Cromolyn%20Sodium_prntlbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18887slr020_intal_lbl.pdfCurator's Comment: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/090954s000lbl.pdf |http://www.rxlist.com/crolom-drug.htm | https://www.ncbi.nlm.nih.gov/pubmed/8809432
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/75-271_Cromolyn%20Sodium_prntlbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18887slr020_intal_lbl.pdf
Curator's Comment: description was created based on several sources, including:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/090954s000lbl.pdf |http://www.rxlist.com/crolom-drug.htm | https://www.ncbi.nlm.nih.gov/pubmed/8809432
Cromolyn is a mast cell stabilizer. In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells, which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell. Cromolyn is indicated in the management of patients with mastocytosis, prophylaxis (long-term control) of bronchial asthma, prevention of exercise-induced bronchospasm, prevention and treatment of seasonal and perennial allergic rhinitis The most frequently reported adverse reactions attributed to cromolyn sodium treatment were: throat irritation or dryness, bad taste, cough, wheeze, nausea.
CNS Activity
Sources: www.ncbi.nlm.nih.gov/pubmed/19004805https://www.ncbi.nlm.nih.gov/pubmed/8809432
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1293267 |
|||
Target ID: Chloride channels |
19.0 µM [IC50] | ||
Target ID: GO:0070509 |
|||
Target ID: GO:0045576 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CROMOLYN SODIUM Approved UseGASTROCROM is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. Launch Date1994 |
|||
| Preventing | CROMOLYN SODIUM Approved UseCromolyn sodium is a prophylactic agent indicated in the management of patients with bronchial
asthma. Launch Date1994 |
|||
| Palliative | CROMOLYN SODIUM Approved UseCromolyn sodium is used to prevent and relieve nasal symptoms of hay fever and other nasal allergies. Launch Date1994 |
|||
| Primary | CROMOLYN SODIUM Approved UseCromolyn sodium ophthalmic solution is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. Launch Date1994 |
|||
| Preventing | CROMOLYN SODIUM Approved UseTo help prevent asthma attacks. Launch Date1994 |
|||
| Preventing | NASALCROM Approved UseTo prevent and relieve nasal symptoms of hay fever and other nasal allergies Launch Date1997 |
|||
| Palliative | OPTREX Approved UseOptrex is used for the prevention and treatment of eye allergies. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.24 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/ |
17.1 mg single, respiratory dose: 17.1 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN |
CROMOLYN cerebrospinal fluid | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
0.34 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/ |
34.2 mg single, respiratory dose: 34.2 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN |
CROMOLYN cerebrospinal fluid | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
46.69 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/ |
17.1 mg single, respiratory dose: 17.1 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
96.75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/ |
34.2 mg single, respiratory dose: 34.2 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
156 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32944204/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
236 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32944204/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
338 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32944204/ |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
526 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32944204/ |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/ |
17.1 mg single, respiratory dose: 17.1 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/ |
34.2 mg single, respiratory dose: 34.2 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN |
CROMOLYN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
62.4 mg 1 times / day multiple, intranasal Dose: 62.4 mg, 1 times / day Route: intranasal Route: multiple Dose: 62.4 mg, 1 times / day Sources: |
unhealthy, 25 years (range: 5-51 years) n = 45 Health Status: unhealthy Age Group: 25 years (range: 5-51 years) Sex: M+F Population Size: 45 Sources: |
|
200 mg 4 times / day multiple, oral Recommended Dose: 200 mg, 4 times / day Route: oral Route: multiple Dose: 200 mg, 4 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: mastocytosis Age Group: adult Sources: |
|
2 % multiple, ophthalmic |
unhealthy, adult n = 37 Health Status: unhealthy Condition: allergic conjunctivitis Age Group: adult Population Size: 37 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pro-drugs for the oral delivery of disodium cromoglycate. | 1988 Jan |
|
| [Effects of orally available prodrug of cromoglycic acid on collagen-induced arthritis mice]. | 1999 Oct |
|
| [A sniffing child]. | 2001 |
|
| Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerant asthma. | 2001 Aug |
|
| Antibacterial activity of apical surface fluid from the human airway cell line Calu-3: pharmacologic alteration by corticosteroids and beta(2)-agonists. | 2001 Aug |
|
| Asthma symptoms, morbidity, and antiinflammatory use in inner-city children. | 2001 Aug |
|
| Determination of sodium cromoglycate in human plasma by liquid chromatography-mass spectrometry in the turbo ion spray mode. | 2001 Dec 25 |
|
| [Exercise-induced asthma. The spray belongs in the "athletic shoe"]. | 2001 Jul 19 |
|
| Therapy choices beyond antihistamines. Vasomotor rhinitis. | 2001 Nov |
|
| Effect of specific immunotherapy versus loratadine on serum adhesion molecules. | 2001 Oct |
|
| Antiallergic/antiasthmatic effect of novel antiallergic hexapeptide-95/220 in various experimental models. | 2001 Sep |
|
| The importance of control in asthma management: do leukotriene receptor antagonists meet patient and physician needs? | 2001 Sep-Oct |
|
| Topical treatment of pyoderma gangraenosum. | 2002 |
|
| In vitro deposition of the respirable fraction of dry powder inhalations determined by laser diffractometry and inertial impaction. | 2002 Aug |
|
| Inhaled sodium cromoglycate in children with asthma. | 2002 Aug |
|
| Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. | 2002 Aug |
|
| 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. | 2002 Aug 5 |
|
| Efficacy and safety of inhaled steroid and cromone treatment in school-age children: a randomized pragmatic pilot study. | 2002 Feb |
|
| Using case management to increase antiinflammatory medication use among a managed care population with asthma. | 2002 Feb |
|
| Effects of topical anti-inflammatory and antiallergic eyedrops on prostaglandin E2-induced aqueous flare elevation in pigmented rabbits. | 2002 Jul |
|
| Water dynamics in channel hydrates investigated using H/D exchange. | 2002 Jul 25 |
|
| Single dose of ketotifen fumarate .025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitis. | 2002 Jul-Aug |
|
| The combination of nebulized sodium cromoglycate and salbutamol in the treatment of moderate-to-severe asthma in children. | 2002 Jun |
|
| Efficacy and patient satisfaction with cromolyn sodium nasal solution in the treatment of seasonal allergic rhinitis: a placebo-controlled study. | 2002 Jun |
|
| Improved strategies and new treatment options for allergic rhinitis. | 2002 Jun |
|
| Allergic rhinitis remains an important disease. | 2002 Jun |
|
| One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma. | 2002 Jun |
|
| (S)nifty treatment for pollen allergies. | 2002 Jun |
|
| Balancing safety and efficacy in the treatment of pediatric asthma. | 2002 Jun |
|
| Generalized bullae in an infant. | 2002 Jun |
|
| Management of suspected acute viral upper respiratory tract infection in children with intranasal sodium cromoglicate: a randomised controlled trial. | 2002 Jun 22 |
|
| [Exercise-induced asthma. Not a reason to be benched]. | 2002 Jun 27 |
|
| Fluticasone for the treatment of symptomatic bronchial asthma in children treated with sodium cromogylate--a prospective, randomised trial. | 2002 Jun 28 |
|
| The effect of disodium cromoglycate, budesonide, and cyclosporin A on interleukin-4, interleukin-5, and interleukin-13 secretions in Der p I-stimulated T cells from house dust mite-sensitive atopic and nonatopic individuals. | 2002 Mar-Apr |
|
| Perinatal immunomodulation. | 2002 May |
|
| Management of allergic and nonallergic rhinitis. | 2002 May |
|
| Effect of interventions during acute respiratory syncytial virus bronchiolitis on subsequent long term respiratory morbidity. | 2002 May |
|
| Ischaemic preconditioning and mast cell histamine release: microdialysis of isolated rat hearts. | 2002 May |
|
| Floating a metered-dose inhaler is not an accurate measure of remaining medicine. | 2002 May |
|
| Relative lung and systemic bioavailability of sodium cromoglycate inhaled products using urinary drug excretion post inhalation. | 2002 May |
|
| Nebulized budesonide inhalation suspension compared with cromolyn sodium nebulizer solution for asthma in young children: results of a randomized outcomes trial. | 2002 May |
|
| Airway hyperresponsiveness to adenosine induced by lipopolysaccharide in Brown Norway rats. | 2002 May |
|
| Long-term management of asthma in children: effectiveness of inhaled corticosteroids compared to other medications. | 2002 Nov |
|
| Inhalation and deposition of nebulized sodium cromoglycate in two different particle size distributions in children with asthma. | 2002 Nov |
|
| A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. | 2002 Oct |
|
| Sodium cromoglycate and doxantrazole are oxygen radical scavengers. | 2002 Oct |
|
| Mast cells as a target of rheumatoid arthritis treatment. | 2002 Sep |
|
| [Enhancing effects of ion-pair complexes on skin permeation of cromolyn in vitro]. | 2002 Sep |
|
| The role of sodium cromolyn in treatment of paraquat-induced pulmonary fibrosis in rat. | 2002 Sep |
|
| Mast cells mediate the microvascular inflammatory response to systemic hypoxia. | 2003 Jan |
Sample Use Guides
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:27:09 GMT 2023
by
admin
on
Sat Dec 16 05:27:09 GMT 2023
|
| Record UNII |
W7074H45IM
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID70149394
Created by
admin on Sat Dec 16 05:27:09 GMT 2023 , Edited by admin on Sat Dec 16 05:27:09 GMT 2023
|
PRIMARY | |||
|
W7074H45IM
Created by
admin on Sat Dec 16 05:27:09 GMT 2023 , Edited by admin on Sat Dec 16 05:27:09 GMT 2023
|
PRIMARY | |||
|
110816-78-9
Created by
admin on Sat Dec 16 05:27:09 GMT 2023 , Edited by admin on Sat Dec 16 05:27:09 GMT 2023
|
PRIMARY | |||
|
196638
Created by
admin on Sat Dec 16 05:27:09 GMT 2023 , Edited by admin on Sat Dec 16 05:27:09 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
